
Court Ruling Limits Ozempic Copies in Favor of FDA, Novo Nordisk
A federal court in Texas has
The ruling, issued April 24 in the U.S. District Court for the Northern District of Texas, denied a request from the Outsourcing Facilities Association (OFA) to block the FDA's recent
That decision effectively ended a temporary allowance for pharmacies to compound semaglutide-based drugs for patients. Semaglutide is the active ingredient in Ozempic and Wegovy. Court documents remain
According to a KFF
Without the shortage designation, pharmacies may no longer produce compounded versions of semaglutide except in rare circumstances. Smaller 503A pharmacies must stop immediately, while larger outsourcing facilities have until May 22 before facing FDA enforcement.
The FDA
said in
had been in shortage since 2022 due to 'increased demand.'
Related Stories
2/24/2025
1/29/2025
Several other lawsuits regarding another popular weight loss medication called tirzepatide [brand name Zepbound and Mounjaro] are also ongoing, as its manufacturer, Eli Lilly, has taken a similar legal approach as Novo Nordisk. The FDA
In an emailed statement to The Epoch Times on Friday, the Outsourcing Facilities Association said it was 'deeply disappointed' by the court's decision.
'The U.S. District Court for the Northern District of Texas misapprehended or failed to take into consideration the clear and convincing evidence that demonstrates that the manufactured supply of semaglutide is not able to meet the enormous demand in the U.S.,' said OFA Chairman Lee H. Rosebush.
'We look forward to the opportunity to introduce this evidence again through the legal process and in discussions with the FDA. We will not stop in our efforts to ensure that patients can get access to this vital medication.'
Novo Nordisk said the ruling supports the FDA's conclusion that the supply of its brand-name semaglutide products is sufficient to meet U.S. demand.
'The court's ruling left in place FDA's prior determination that all doses of Wegovy® and Ozempic® are fully available nationwide and that Novo Nordisk's supply of these FDA-approved medicines is meeting or exceeding current and projected nationwide patient demand,' the company said in the statement.
'With the FDA's resolution of the shortage of Ozempic® and Wegovy®, as left in place by this court ruling, it is illegal under U.S. compounding laws to make or sell knockoff 'semaglutide drugs,' with rare exceptions.'
The company said it has filed 111 lawsuits in federal courts across 32 states to stop the marketing and sale of what it describes as knockoff or misbranded compounded versions.
'We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage of Wegovy® and Ozempic® is resolved,' said Steve Benz, Novo Nordisk's general counsel.
'FDA's determination was based on a thorough review of Novo Nordisk's stable and growing supply of these important FDA-approved medicines. With the end of the shortage of Wegovy® and Ozempic®, no patient should have to be exposed to unsafe, inauthentic 'semaglutide' drugs. Patient safety remains a top priority for Novo Nordisk, and the extensive nationwide legal actions we have taken to protect Americans from the health risks posed by illegitimate 'semaglutide' drugs are working.'
While brand-name drugs such as Ozempic and Wegovy can cost
Novo Nordisk says its legal efforts are aimed at protecting patients from unsafe or unregulated products, including those made with synthetic semaglutide from overseas suppliers, such as manufacturers in China that have not been reviewed by the FDA.
Novo Nordisk and the FDA did not respond to additional questions from The Epoch Times before publication time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
JumpCloud & Deel IT Unite for Seamless Provisioning
LOUISVILLE, Colo., June 10, 2025 /PRNewswire/ -- JumpCloud Inc. has partnered with Deel IT to simplify global device management. This collaboration helps businesses manage devices and security for employees worldwide. Managing IT for global teams brings unique challenges. Traditional methods struggle with outdated, centralized systems that can't adapt to diverse international operations and local regulations. Companies deal with problems such as: Time-consuming manual tasks Complex compliance rules Inventory issues Slow onboarding for new international hires IT teams can now conquer operational hurdles and security concerns with a powerful combined solution from JumpCloud and Deel IT, designed to streamline their workflows. Through this partnership, customers will gain key advantages, including: Receive ready-to-use devices: Your new devices arrive pre-configured with all necessary security settings and automated updates, enabling immediate and secure use. Benefit from day-one security compliance: You can be confident that all your devices automatically meet your security standards from the moment they're deployed, significantly reducing your risk exposure. Simplify your global device management: You can offload the complexities of managing devices worldwide—from initial procurement all the way through to repurposing and secure disposal—freeing up your IT team for other priorities. Application management: JumpCloud ensures secure software access, saving IT teams time. "This partnership with JumpCloud unlocks a new level of simplicity for global teams, no matter where they work," said Sami Bouremoum, general manager, Deel IT. "By streamlining device provisioning and security across borders, we're helping IT teams move faster and deliver a seamless, secure experience to distributed team members, wherever they are in the world." This integrated approach helps businesses expand into new talent regions with confidence. IT teams can onboard employees and manage equipment consistently, regardless of location. This reduces operational costs and enhances security. "Running a global business requires intelligent IT solutions," said Joel Rennich, senior vice president, product management, JumpCloud. "Our partnership with Deel IT provides a powerful way to manage devices and keep teams secure, no matter where they are." To learn more about combining JumpCloud and Deel IT to support your workforce, visit the blog post here. About Deel Deel is the all-in-one payroll and HR platform for global teams. Built for the way the world works today, Deel combines payroll, HRIS, compliance, benefits, performance, and equipment management into one seamless platform. With AI-powered tools and a fully owned payroll infrastructure, Deel supports every worker type in 150+ countries—helping businesses scale smarter, faster, and more compliantly. Discover how Deel makes global work simple at About JumpCloud JumpCloud® delivers a unified identity, device, and access management platform that makes it easy to securely manage identities, devices, and access across your organization. With JumpCloud, IT teams and MSPs enable users to work securely from anywhere and manage their Windows, Apple, Linux, and Android devices from a single platform. Learn more: Follow us: Blog | Community | Podcast | X | LinkedIn | YouTube | Resources Click here to get started with JumpCloud Contact For JumpCloud Josie Judy press@ View original content: SOURCE JumpCloud, Inc.


Indianapolis Star
31 minutes ago
- Indianapolis Star
New to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global Expansion
NEW YORK, NY / ACCESS Newswire New to The Street, the nationally televised business show airing on Bloomberg and FOX Business, proudly features Synergy CHC Corp. (NASDAQ:SNYR) as a spotlight company, highlighting the brand's strategic expansion in the global functional beverage market. The feature follows Synergy's high-profile appointment of Damian Marano, a former Coca-Cola executive, as the company's new Vice President of Beverage. Marano, a seasoned global brand architect with over 20 years at Coca-Cola and founder of Docklight Brands, joins Synergy CHC to lead the international rollout of its FOCUSfactor® Energy Drink, a fast-emerging player in the $30B+ clean-energy beverage space. 'New to The Street's mission has always been to introduce audiences to the most dynamic companies shaping tomorrow's economy,' said Jane King, anchor at New to The Street. 'Synergy's aggressive expansion strategy, coupled with leadership from a Coca-Cola veteran, puts them in a strong position to disrupt the functional beverage category.' FOCUSfactor® Energy Drink is powered by brain-boosting nootropics and essential vitamins, building on the brand equity of Synergy's best-selling FOCUSfactor® supplement line, currently sold in major retailers like Costco, Amazon, Walmart, CVS, and Walgreens. Damian Marano commented, 'Having led growth initiatives for some of the world's most recognizable beverage brands, I see a massive opportunity in FOCUSfactor® to define the next wave of clean, functional performance drinks.' The appointment follows the recent addition of Erik Shields to Synergy's beverage team and aligns with the company's strategy to scale its consumer health portfolio globally. The New to The Street feature will air on Bloomberg TV this Saturday at 6:30 PM ET and FOX Business next week, with segments available on YouTube and social platforms to more than 2.5 million subscribers. About Synergy CHC Corp. Synergy CHC Corp. (NASDAQ: SNYR) is a consumer health and wellness company marketing a portfolio of trusted brands including FOCUSfactor®, Flat Tummy®, Sneaky Vaunt®, and Hand MD®. With a footprint in North America, Canada, and the UK, Synergy is focused on driving innovation across supplements, beauty, and functional beverages. Learn more at About New to The Street New to The Street is one of the longest-running business television brands in the U.S., broadcasting sponsored content on FOX Business, Bloomberg, and through over 2.5 million YouTube subscribers. The show features innovative public and private companies delivering news, insights, and investment perspectives across global markets. Media Contacts: Monica Brennan New to The Street Media Relations Monica@ Investor Relations Synergy CHC Corp. ir@ SOURCE: New To The Street View the original press release on ACCESS Newswire

Yahoo
41 minutes ago
- Yahoo
Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution
Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution Fleurieux-sur-l'Arbresle - France - June 5, 2025 at 6 p.m. Safe Group, a leading player in the field of medical devices for spine surgery, is pleased to announce that Frida, the innovative cervical plate developed by SpineUp, has received 510(k) clearance from the Food and Drug Administration (FDA). This clearance marks a crucial step in SpineUp's expansion into the North American market, and testifies to its ongoing commitment to providing cutting-edge medical solutions. Frida is a new-generation cervical plate offering high adaptability with a multiplicity of plate and screw sizes. Thanks to this technology, healthcare professionals will be able to offer more personalized treatments, tailored to the specific needs of surgeons and their patients. FDA 510(k) clearance is the result of several years of research and development. This certification attests to the safety and efficacy of the Frida solution, which complies with the FDA's strict standards and is due to be marketed by the end of the year. « In view of the merger of Safe's subsidiaries with SpineUp, we are delighted that this authorization has been granted and that SpineUp has taken a major step forward, validating the company's commitment to innovation and improving patient care," says Victor Humberdot, Chairman of Safe Group. 'This new step heralds new business opportunities for SpineUp and its subsidiaries Safe Orthopaedics and Safe Medical, increased synergy and a stronger foothold in the U.S.' comments Philippe Laurito, President of SpineUp Inc. About Safe Group Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopedic surgeries. The group employs approximately 100 Orthopaedics develops and manufactures kits combining sterile implants and ready-to-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs. Protected by 15 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics has subsidiaries in the United Kingdom, Germany, the United more information: Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France and in Tunisia, offering numerous industrial services: industrialization, machining, finishing and sterile more information: ContactsSAFE GROUP AELYON ADVISORSinvestors@ safe@ Attachment Safe_PR_SpineUp_FDA